Work

IgM-enriched intravenous immunoglobulin and progression from sepsis to septic shock: a multicenter retrospective cohort study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Progression from sepsis to septic shock remains a major determinant of adverse outcome despite timely antimicrobial therapy, source control, and organ support. IgM-enriched intravenous immunoglobulin (IVIG) has potential immunomodulatory and pathogen-neutralizing effects, but prior studies have been limited by biological heterogeneity and non-comparable control groups. We evaluated whether early adjunctive IgM-enriched IVIG was associated with a lower risk of progression from sepsis to septic shock, with the primary comparison restricted to patients with predefined early immune dysfunction. We performed a multicenter retrospective cohort study of adults admitted to participating tertiary intensive care units between June 2021 and June 2023 with Sepsis-3-defined sepsis but without septic shock at index ICU admission. Patients presenting with septic shock were excluded from the progression cohort ( n = 148). Twenty-eight patients who initiated IVIG but died before completing the 3-day regimen were excluded from the treatment-completer cohort; 18 baseline-eligible patients were retained in the initiation-based comparison. Sepsis diagnosis was systematically reassessed at 72 h using the complete clinical course, microbiological/culture data, evidence of infection, and SOFA-based organ dysfunction. Immune dysfunction was defined using laboratory values obtained within 4 h of ICU admission as an absolute lymphocyte count < 0.8 × 10^9/L and/or serum IgM < 0.6 g/L. The primary analysis compared immune phenotype-positive patients who received early IgM-enriched IVIG ( n = 147) with immune phenotype-positive patients who did not receive IVIG because the treatment cost was not covered by the applicable insurance/reimbursement system ( n = 43). Immune phenotype-negative patients receiving standard care ( n = 196) were retained as a descriptive reference group. The primary outcome was progression to Sepsis-3 septic shock within 28 days. A parsimonious multivariable logistic regression was the primary adjusted analysis; inverse probability of treatment weighting (IPTW) was used only as a sensitivity analysis. The final analytic cohort included 386 patients. In the eligibility-restricted initiation-based sensitivity analysis, progression to septic shock occurred in 51/165 (30.9%) IVIG initiators versus 13/43 (30.2%) untreated immune phenotype-positive patients (RR 1.02, 95% CI 0.62–1.70; Fisher exact P = 1.000). In the original treatment-completer comparison, shock occurred in 33/147 (22.4%) versus 13/43 (30.2%) (RR 0.74, 95% CI 0.43–1.28; Fisher exact P = 0.315). The prespecified adjusted OR was 0.63 (95% CI 0.29–1.38; P = 0.245). Complete-case IPTW yielded an OR of 0.65 (95% CI 0.30–1.41; robust P = 0.279). Neither comparison supports a causal inference or a demonstrated benefit. The eligibility-restricted initiation-based comparison showed similar septic shock incidence among IVIG initiators and untreated phenotype-positive patients, whereas the original treatment-completer comparison showed a numerically lower, non-significant incidence. Both comparisons are vulnerable to survival-related selection and time-zero misalignment and do not establish treatment efficacy.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7236637848
FWCI:
Cites:
Cited by:
Related to: 10